πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

Showing page 156 of 857 Β· Phase 3 first, then by program name

  1. Reagila 1.5 mg hard capsules, For the purpose of the clinical study a placebo formulation was prepared using the same white hard gelatine capsule shell., Reagila 3 mg hard capsules, Cariprazine 0.5 mg capsules, hard, Reagila 4.5 mg hard capsules

    Gedeon Richter Plc.

    Adolescent Patients (13 to 17 years of age) with Schizophrenia

    phase 3 small molecule active

    1 trial

  2. Realgar-Indigo naturalis formula

    The First People's Hospital of Lianyungang

    Acute Promyelocytic Leukemia

    phase 3 small molecule active

    1 trial

  3. Reblozyl 75 mg powder for solution for injection, Reblozyl 25 mg powder for solution for injection

    Celgene Europe Limited

    Myelodysplastic syndrome

    phase 3 small molecule active

    1 trial

  4. Reblozyl 75 mg powder for solution for injection, Reblozyl 25 mg powder for solution for injection

    Celgene Europe Limited

    myelodysplastic syndrome (MDS); beta (Ξ²)-thalassemia (THAL); myelofibrosis (MF)

    phase 3 small molecule active

    1 trial

  5. Recombinant 14-Valent Human Papillomavirus Vaccine（Insect CellοΌ‰

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HPV InfectioN

    phase 3 mab active

    1 trial

  6. Recombinant Anti-IL-1Ξ² Humanized Monoclonal Antibody Injection 200 mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Acute Gout

    phase 3 small molecule active

    2 trials

  7. Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  8. Recombinant Factor VIII (BAY81-8973)

    Bayer HealthCare AG

    Blood Coagulation Disorders

    phase 3 mab completed

    1 trial

  9. Recombinant Factor VIIa

    United Therapeutics Europe Ltd

    Burns

    phase 3 small molecule completed

    1 trial

  10. Recombinant Factor VIIa BI (rFVIIa BI)

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  11. Recombinant Human Albumin Injection

    The First People's Hospital of Lianyungang

    Hepatic Ascites

    phase 3 mab completed

    2 trials

  12. Recombinant Human Thrombopoietin (rhTPO)

    The First People's Hospital of Lianyungang

    Immune Thrombocytopenia

    phase 3 small molecule completed

    1 trial

  13. Recombinant Human VEGF Receptor-Fc Fusion Protein

    Biotech Pharmaceutical Co.,

    Neovascular Age-related Macular Degeneration

    phase 3 mab completed

    1 trial

  14. Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)

    BRIGHT MINDS BIOSCIENCES INC.

    Human Papillomavirus Infection

    phase 3 mab active

    1 trial

  15. Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Respiratory Syncytial Virus (RSV)

    phase 3 mab active

    1 trial

  16. Recombinant SARS-CoV-2 fusion protein vaccine (V-01)

    Livzon Pharmaceutical Group

    COVID-19 Pandemic

    phase 3 mab active

    1 trial

  17. Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)

    Takeda

    Hemophilia A

    phase 3 mab terminated

    1 trial

  18. Recombinant factor IX

    Takeda

    Hemophilia B

    phase 3 mab completed

    1 trial

  19. Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  20. Recombinant human luteinizing hormone (r-hLH)

    Merck KGaA, Darmstadt, Germany

    Hypogonadism

    phase 3 small molecule completed

    1 trial

  21. Recombinant human tissue kallikrein

    DiaMedica Therapeutics

    Acute Stroke

    phase 3 small molecule active

    1 trial

  22. Recombinant von Willebrand factor (rVWF)

    Takeda

    Von Willebrand Disease

    phase 3 mab completed

    2 trials

  23. Recommended treatment schedule

    Prime Medicine

    COVID-19

    phase 3 small molecule terminated

    1 trial

  24. Recovery Management Checkups (RMC)

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 3 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources